Participant‐ or parent‐reported global assessment of disease severity · adults and children with atopic eczema and inhalant allergen sensitisation
1 finding from 1 review
Participant‐ or parent‐reported specific symptoms of eczema · adults and children with atopic eczema and inhalant allergen sensitisation
1 finding from 1 review
Any systemic reactions during therapy · adults and children with atopic eczema and inhalant allergen sensitisation
Specific allergen immunotherapy showed no clear difference in adverse events ‐ any systemic reaction compared with no immunotherapy (moderate certainty).
1 finding from 1 review
Investigator‐ or physician‐rated global assessment of disease severity · adults and children with atopic eczema and inhalant allergen sensitisation
It is very uncertain whether specific allergen immunotherapy changes investigator‐ or physician‐rated global assessment of disease severity compared with no immunotherapy (very low certainty).
1 finding from 1 review
Investigator‐ or physician‐rated eczema severity using a published scale · adults and children with atopic eczema and inhalant allergen sensitisation
1 finding from 1 review
Participant or parent‐rated eczema severity using a published scale · adults and children with atopic eczema and inhalant allergen sensitisation
1 finding from 1 review
Overall survival† · people with cutaneous melanoma
Biochemotherapy showed no clear difference in overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.94 [0.84, 1.06]
1317 participants
High
Progression‐free survival · people with cutaneous melanoma
Biochemotherapy leads to lower progression‐free survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.9 [0.83, 0.99]
964 participants
High
Tumour response · people with cutaneous melanoma
Biochemotherapy leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
RR 1.36 [1.12, 1.66]
770 participants
High
Toxicity (≥ G3) · people with cutaneous melanoma
Biochemotherapy leads to higher toxicity (≥ G3) compared with chemotherapy (high certainty).
1 finding from 1 review
RR 1.35 [1.14, 1.61]
631 participants
High
Overall survival† · people with cutaneous melanoma
Polychemotherapy showed no clear difference in overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.99 [0.85, 1.16]
594 participants
High
Progression‐freesurvival† · people with cutaneous melanoma
Polychemotherapy showed no clear difference in progression‐freesurvival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 1.07 [0.91, 1.25]
398 participants
High
Tumour response · people with cutaneous melanoma
Polychemotherapy probably leads to higher tumour response compared with chemotherapy (moderate certainty).
1 finding from 1 review
RR 1.27 [1.02, 1.58]
1885 participants
Moderate
Toxicity (≥ G3) · people with cutaneous melanoma
Polychemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
1 finding from 1 review
RR 1.97 [1.44, 2.71]
390 participants
Moderate
Proportion of participants cleared or almost cleared ‐ · chronic palmoplantar pustulosis
1 finding from 1 review
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants achieving a 50% reduction in disease severity · chronic palmoplantar pustulosis
1 finding from 1 review
Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis
1 finding from 1 review